Evidence map›Paper›PMID 38644901›Full record

ReviewHeliyon2024

Advances in the chemical constituents, pharmacological activity, and clinical application of

Mingxin Guo, Jiaqi Zeng, Zhanle Wang, Ying Shen

Open access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Heliyon, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 1 pooled it
2.3field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 1 synthesis or guideline pooled it, 10 citations in OpenAlex.

  1. Pooled it
  2. Component characterization ofFrontiers in cellular and infection microbiology · 2025
    Article
  3. Review
  4. Mechanistic Exploration ofPharmaceuticals (Basel, Switzerland) · 2024
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Mingxin GuoDepartment of Pharmacy, The Affiliated Yixing Hospital of Jiangsu University, Yixing, 214200, China.
Jiaqi ZengDepartment of Pharmacy, The Affiliated Yixing Hospital of Jiangsu University, Yixing, 214200, China.
Zhanle WangPharmacology Laboratory, School of Pharmacy, Guangdong Pharmaceutical University, Guangzhou, 510006, China.
Ying ShenDepartment of Pharmacy, The Affiliated Yixing Hospital of Jiangsu University, Yixing, 214200, China.
Jiangsu University · CNGuangdong Pharmaceutical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

AstilbinChemical constituentsClinical applicationPharmacological activityQuality markers (Q-markers)Research progressSmilacis Glabrae Rhizoma (SGR)

Identifiers

PMID38644901
PMCPMC11031832
OpenAlexW4394760608

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.